Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) today announced that its Board of Directors resolved at a meeting held on February 28, 2022, to establish a holding company in China as a wholly owned subsidiary.

The Company decided to establish a holding company, "Sumitomo Pharma (China) Co., Ltd." in China as a wholly owned subsidiary to manage and enhance our China business.

Notice of Establishment of Holding Company in China

DSPC-NP-CI-22-03-0007